United States - English - NLM (National Library of Medicine)

neobourne pharma lp - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 10 g in 100 g

United States - English - NLM (National Library of Medicine)

riteaid - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 200 mg in 1 g

United States - English - NLM (National Library of Medicine)

galentic pharma (india) priva te limited - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 200 mg in 1 g - - helps treat and prevent diaper rash. - dries the oozing and weeping of; - poison ivy - poison oak - poison sumac - conditions worsens - symptoms last more than 7 days or clear up and occur again in a few days, consult a physician. - over large areas of the body - if you are allergic to any of these ingredients - deep or puncture wounds - animal bites - serious burns

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 200 mg in 1 g - skin protectant uses:

United States - English - NLM (National Library of Medicine)

walgreen co - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 532 mg in 1 g - skin protectant • helps treat and prevent diaper rash • protects chafed skin due to the diaper rash and helps seal out wetness - condition worsens - symptoms last more than 7 days or clear up and occur again within a few days

United States - English - NLM (National Library of Medicine)

chain drug manufacturing assn - zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37) - zinc gluconate 1 [hp_x]

Australia - English - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - sodium chloride, quantity: 2.83 mg/ml; glucose monohydrate, quantity: 22 mg/ml; calcium carbonate, quantity: 200 microgram/ml (equivalent: calcium, qty 80 microgram/ml); potassium citrate, quantity: 1.46 mg/ml (equivalent: potassium, qty 529 microgram/ml); manganese sulfate monohydrate, quantity: 1.6 microgram/ml (equivalent: manganese, qty 507 ng/ml); copper gluconate, quantity: 2.1 microgram/ml (equivalent: copper, qty 300 ng/ml); zinc sulfate monohydrate, quantity: 5.5 microgram/ml (equivalent: zinc, qty 2 microgram/ml); citric acid monohydrate, quantity: 4.31 mg/ml; ferrous sulfate, quantity: 3.13 microgram/ml (equivalent: iron, qty 1 microgram/ml); dried magnesium sulfate, quantity: 374 microgram/ml (equivalent: magnesium, qty 50 microgram/ml) - oral liquid - excipient ingredients: potassium sorbate; sodium benzoate; sucralose; purified water; flavour; colour - decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance ; helps restore body electrolyte balance ; decrease/reduce/relieve muscle cramps ; helps enhance/improve/promote/increase physical/exercise performance

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6)] risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate.  the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc.  parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration (2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients.  in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoire aguettant - zinc gluconate 6,97 mg/ml - eq. zinc 1 mg/ml - concentrate for solution for infusion - 1 mg/ml - zinc gluconate 6.97 mg/ml - zinc gluconate

Malta - English - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - potassium iodide, copper chloride, zinc chloride, manganese chloride, sodium fluoride, sodium selenite - concentrate for solution for infusion - potassium iodide 1.31 µg/ml copper chloride 53.7 µg/ml zinc chloride 521 µg/ml manganese chloride 3.6 µg/ml sodium fluoride 126 µg/ml sodium selenite 4.38 µg/ml - blood substitutes and perfusion solutions